



## **Trendlines Exits MitrAssist Ltd.**

**MISGAV, Israel, 13 November, 2017** -- The Trendlines Group (the “Group”) (SGX: 42T; OTCQX: TRNLY), a leading Israeli investment and innovation commercialization company, focused on early-stage, high growth innovation-based medical and agricultural technologies, today announced the sale of its MitrAssist Ltd. (“MitrAssist”) holdings to Wai Tech (Hong Kong) Holding Ltd. (“Wai Tech”). MitrAssist is developing a solution to percutaneous repair of Mitral Regurgitation.

With the completion of the transaction, the Group has sold its entire shareholding in MitrAssist, with total pre-tax proceeds of approximately US\$1.15 million. The transaction was completed in two stages. In the first stage, Trendlines received US\$0.57 million. In the second stage, now completed, Trendlines received approximately US\$0.58 million, resulting in an after-tax gain of US\$0.5 million. Proceeds from the MitrAssist exit will serve to further strengthen the Group's cash position and are intended to be used for continuing operations and investments of the Group.

Commenting on the exit from MitrAssist, Trendlines Chairman and CEO, Todd Dollinger, said, “We are pleased to announce Wai Tech’s acquisition of our interest in MitrAssist, our third exit since September 2017. This is a very good time for Trendlines as we work closely with the more mature companies in our portfolio to position them for exit. Proceeds from the MitrAssist exit will serve to further strengthen our cash position. The MitrAssist exit yielded an estimated return of 2.1X\* with a 12% internal rate of return (IRR) for the Group; the estimated return of all seven exits completed by the Group to date is 10.1X\* with a weighted average IRR of 95%.”

\*Estimated return represents the multiple of exit proceeds over Trendlines’ cash and non-cash investment in the exited company: (i) our cash investment and (ii) estimated value of services provided to the exited company.

###

### **About Trendlines**

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfil its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines’ shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

**Investor Contact Information****Israel:**

Judith Kleinman  
Director, Investor Relations & Corporate Communications  
The Trendlines Group  
judith@trendlines.com  
Tel: +972.72.260.7000

**Singapore:**

Reyna MEI Financial PR  
reyna@financialpr.com.sg  
Tel: +65.6438.2990

-The End-

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg)